The Ontario Public Drug Programs (OPDP) began funding INFLECTRA™ (infliximab) as a Limited Use (LU) benefit for eligible ODB recipients, effective February 25, 2016, for the following indications:
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
The LU criteria are posted in the eFormulary which can found on the ministry’s website at:
http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx
The funding of ... Read More
15
Mar2016
15
Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 11, 2016 for Hospira HealthCare Corporation’s subsequent entry biologic (SEB), INFLECTRA™ (infliximab).
According to the CADTH website, Hospira is seeking public reimbursement for Crohn’s disease and Ulcerative Colitis.
For those interested in providing ... Read More
10
Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, 2016 for etanercept - the subsequent entry biologic (SEB) version of Amgen’s ENBREL™. For those interested in providing patient input, please complete the CDR Patient Input Submission.
According to the ... Read More
10
Mar2016
The Ontario Ministry of Health and Long-Term Care (the ‘ministry’) is proposing to update recipient cost-sharing arrangements for non-low income seniors as well as expand eligibility for the Seniors Co-Payment Program under the Ontario Drug Benefit (ODB) program.
Proposed amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act ... Read More
26
Feb2016
Revised Procedures for CDR and pCODR
For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ... Read More
23
Feb2016
In a recent update released to their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced 2 significant developments:
The Federal Drug Plans are now participating in the pCPA; and
The Office of the pCPA (the Office) is now fully staffed.
On January 19, 2016 the Government of Canada issued a News Release ... Read More
17
Feb2016
Ontario has released the February 2016 Summary of Changes document, which includes the addition of Hospira’s Inflectra at a price of $525.00.
Please see page 4 of the Summary of Changes document for more information regarding the clinical criteria and listing status of Inflectra.
17
Feb2016
Suzanne McGurn, the Executive Officer of the Ontario Public Drug Programs, issued a statement on behalf of the Pan Canadian Pharmaceutical Alliance (pCPA), on February 16, 2016 detailing the end of negotiations with manufacturer Alexion for the listing of Soliris.
Please see the following article for more information.
12
Feb2016
The Alberta Price Confirmation (APC) is issued prior to an Alberta Drug Benefit List (ADBL) publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.
ADBL Effective Date
APC Tentative Issue Date
March 1, 2016
February 2, 2016
April 1, 2016
February 18, ... Read More
12
Feb2016
As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014.
Through this newly named report series, the PMPRB monitors and reports on:
the latest developments in generic drug pricing and markets ... Read More